BUZZ — Iovance hits two — year high after raising annual revenue forecast

* Shares of Iovance Biotherapeutics rise 27.5% to $14, their highest level in more than two years * Co raises FY26 revenue outlook to $410 mln-$420 mln, from a prior forecast of $350 mln-$370 mln * "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint," CEO says * 8 of 10 brokerages rate the stock "buy" or higher and two "hold"; median PT is $11 — data compiled * Including session's move, stock has jumped more than five times in value YTD (Reporting by Anand Gopal in Bengaluru) ((AnandGopal.R@thomsonreuters.com)